Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LGALS3 | P17931 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.43 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.43 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.41 |
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13491439 | 1.00 | MAPK1 (0.56) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL13308281 | 1.00 | MAPK1 (0.56) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL25043094 | 1.00 | MAPK1 (0.56) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL18080805 | 0.91 | LGALS3 (0.58) | MAPK1LGALS3ALDH1A1THRBLGALS8 | |
| SCHEMBL7008766 | 0.88 | MAPK1 (0.67) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL13710843 | 0.88 | MAPK1 (0.67) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL9574469 | 0.88 | MAPK1 (0.67) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL27098396 | 0.88 | MAPK1 (0.67) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL9574473 | 0.88 | MAPK1 (0.67) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL11285039 | 0.88 | MAPK1 (0.67) | MAPK1LGALS3ALDH1A1THRBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137791-A1 | NEURAMINIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR MEDICAL USE | SANKYO COMPANY, LIMITED (JP) | 2002-09-26 | — | — | US | disclosed |
| US-6451766-B1 | SIALIDASE INHIBITORS; INFLUENZA VIRICIDES | SANKYO COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| US-6340702-B1 | SIALIDASE INHIBITORS; ANTIVIRAL COMPOUNDS | SANKYO COMPANY, LIMITED (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-0823428-B1 | Neuraminic acid derivatives, their preparation and their medical use | SANKYO CO (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-0823428-A2 | Neuraminic acid derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1998-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137791-A1 | NEURAMINIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR MEDICAL USE | NEU1, NEU3, NEU2 | MAPK1 2698/4885LGALS3 1049/4885ALDH1A1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.